Rituxirel 500mg/50ml Injection

Rituxirel 500mg/ 50ml Injection is a monoclonal antibody. It is used to treat many types of cancers such as to treat non-hodgkin’s lymphoma and chronic lymphocytic leukemia. It is also indicated to treat moderate-to-severe rheumatoid arthritis in patients. Its active ingredient is rituximab which belongs to the group class of anti-CD20 monoclonal antibodies (immunosuppressive agents).

It works by binding to the CD20 antigen on B cells. The effect helps control B cell proliferation in cancers and modulate immune responses in certain autoimmune disorders. The dosage and administration must be followed as directed by the healthcare professional to ensure safe and effective treatment option.

​

• Non- hodgkin's lymphoma, chronic lymphocytic leukemia and moderate to severe rheumatoid arthritis

Rituxirel 500mg/ 50ml Injection can cause certain side effects some are acute and some are mild. If any of the symptoms persist or worsen, consult the healthcare professional instantly:

• Anemia
• Muscle spasm
• Headache
• Urinary tract infection
• Fever, chills, and shivering
• Inflammation of nasal cavities
• Cough, sore throat
• Loss of hair
• Swelling in the face and body
• Diarrhea and nausea
• Itchy skin
• Increased or decreased blood pressure
• Chest pain
• Hypersensitivity reactions
• Hepatitis B viral infection
• Memory loss, trouble thinking, difficulty walking

• Rituxirel 500mg/ 50ml Injection can be taken with or without food at the fixed time everyday to enhance the effectiveness of the treatment. It can be taken by a nurse in a hospital through the skin through intravenous infusion into a vein under medical supervision.
• Consult the healthcare professional about the correct dosage and duration to ensure safe and effective treatment option.
  

​

• Rituxirel 500mg/ 50ml Injection is an anticancer medication that binds to the CD20 antigen on B lymphocytes. After binding it causes B cell destruction through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct apoptosis.
• This leads to depletion of CD20 positive B cells while sparing stem cells. As a result, it blocks B cells and reduces the size of cancer cells in the body.
  
  

• Grillo-López, A. J., Hedrick, E., Rashford, M., & Benyunes, M. (2002, February). Rituximab: ongoing and future clinical development. In Seminars in oncology (Vol. 29, No. 1, pp. 105-112). WB Saunders. https://www.sciencedirect.com/science/article/abs/pii/S0093775402500853
  
• Cohen, M. D., & Keystone, E. (2015). Rituximab for rheumatoid arthritis. Rheumatology and therapy, 2(2), 99-111. https://pubmed.ncbi.nlm.nih.gov/27747531/
  
• Borker, A., & Choudhary, N. (2011). Rituximab. Indian pediatrics, 48(8), 627-632. https://pubmed.ncbi.nlm.nih.gov/21918268/
  
• Maloney, D. G., Smith, B., & Rose, A. (2002, February). Rituximab: mechanism of action and resistance. In Seminars in oncology (Vol. 29, No. 1, pp. 2-9). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/11842383/
  
• Rezvani, A. R., & Maloney, D. G. (2011). Rituximab resistance. Best practice & research Clinical haematology, 24(2), 203-216. https://pubmed.ncbi.nlm.nih.gov/21658619/​